? SIGN UP for Parade's Daily newsletter to get the latest pop culture news & celebrity interviews delivered right to your inbox ?
A post shared by Crystal Lowe (@officialcrystallowe)
Lowe was the first recipient of Hallmark Media's Make Her Mark program, a mentorship program that trains women in areas of leadership behind the camera. The initiative was the brainchild of another Hallmark actress, Ashley Williams. Lowe shadowed a female director on a Hallmark film before eventually taking on the helm of her own. Her first directing foray for Hallmark was Shifting Gears with The Groomsmen'sTyler Hynes and Wynonna Earp's Katherine Barrell.
She followed up her directorial duties, going behind the camera again on the Hallmark Christmas movie This Time Each Year and then on the franchise Hannah Swensen Mystery series, Pie to Die For. She has since directed projects for Lifetime and Roku, with more projects for Hallmark on the horizon. The studios and entertainment industry professionals have been supportive and accommodating to Lowe amid her diagnosis, allowing her to work remotely while she undergoes treatment. "The entire Hallmark family embraced me fully, and told me that they had my back," Lowe wrote in an essay for People magazine.
October is Breast Cancer Awareness month.
Related: Ashley Williams and Hallmark Channel Put the Focus on Ending Alzheimer's in 'Falling Together'
Hence then, the article about hallmark star opens up about heartbreaking breast cancer diagnosis was published today ( ) and is available on Parade ( Saudi Arabia ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Hallmark Star Opens Up About Heartbreaking Breast Cancer Diagnosis )
Also on site :
- I Thought My Marriage Was Happy. Then My Wife Asked Me to Agree to Something I’d Never Imagined.
- Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025
- Strava eyes IPO as Gen Z trades dating apps for running clubs